compounded tirzepatide microdose Is Microdosing Tirzepatide Safe? vs.

Cardiac myocytes have receptors for sex hormones whose activation can alter the electrical activity of the heart through modulation of ion channels that control the flow of sodium, potassium, and calcium

Clinical trial registration: NCT07058012." Clinical IO biomarker Minimal residual disease Monotherapy P2 data Residual disease Colorectal Cancer Oncology Solid Tumor June 11, 2026 Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (clinicaltrials.gov) - P2 | N=70 | Suspended | Sponsor: Thomas Jefferson University | Recruiting Suspended Trial suspension Basal Cell Carcinoma Head and Neck Cancer Non-melanoma Skin Cancer Oncology June 17, 2026 A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Memorial Sloan Kettering Cancer Center New P1 trial Head and Neck Cancer Nasopharyngeal Carcinoma Oncology Solid Tumor July 22, 2025 TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (IASLC-WCLC 2025) - P2 | "Introduction : SPRINT (NCT03523702) was a multi-center Phase II trial where biomarker-selected (PD-L1 TPS 50%) locally advanced non-small cell lung cancer (LA-NSCLC) patients were treated with 3 cycles of induction therapy with the PD-1 inhibitor pembrolizumab followed by risk-adapted radiotherapy (RT), then consolidation pembrolizumab to complete a 1-year course while chemotherapy was omitted (PMID: 37988638)...Thus, we hypothesize that dual IO with the PD-1 inhibitor cemiplimab plus the LAG-3 inhibitor fianlimab administered before and after thoracic RT, as per the SPRINT approach, has valuable potential as a biomarker-driven treatment regimen for LA-NSCLC patients...Safety will be assessed via a safety-run in phase and extended adverse events collection

But early trials showed the drug led to significant weight loss, because it also slows down the emptying of the stomach, causing people taking it to feel full faster and eat less

Tissue Barriers 4 , e1176822 (2016)

Severe cases may require hospitalization, feeding tubes, or surgical intervention